Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History XGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics XGN

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Exagen Inc

XGN
Current price
6.99 USD -0.01 USD (-0.14%)
Last closed 7.00 USD
ISIN US30068X1037
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 156 832 896 USD
Yield for 12 month +253.03 %
1Y
3Y
5Y
10Y
15Y
XGN
21.11.2021 - 28.11.2021

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. Address: 1261 Liberty Way, Vista, CA, United States, 92081

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.75 USD

P/E Ratio

Dividend Yield

Financials XGN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures XGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+55 641 000 USD

Last Year

+52 548 000 USD

Current Quarter

+15 498 000 USD

Last Quarter

+13 655 000 USD

Current Year

+33 112 000 USD

Last Year

+29 456 000 USD

Current Quarter

+9 123 000 USD

Last Quarter

+8 477 000 USD
EBITDA -12 292 000 USD
Operating Margin TTM -21.71 %
Price to Earnings
Return On Assets TTM -19.21 %
PEG Ratio
Return On Equity TTM -117.50 %
Wall Street Target Price 7.75 USD
Revenue TTM 56 724 000 USD
Book Value 0.36 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 7.50 %
Dividend Yield
Gross Profit TTM 33 637 000 USD
Earnings per share -0.84 USD
Diluted Eps TTM -0.84 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -27.34 %

Stock Valuation XGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.85
Price Sales TTM 2.76
Enterprise Value EBITDA -0.16
Price Book MRQ 23.32

Technical Indicators XGN

For 52 Weeks

1.78 USD 7.95 USD
50 Day MA 6.73 USD
Shares Short Prior Month 204 880
200 Day MA 4.52 USD
Short Ratio 0.92
Shares Short 484 525
Short Percent 1.15 %